Signaling through phosphatidylcholine breakdown.
J. Exton
semanticscholar +1 more source
Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism
Abstract Abnormal epigenetic patterns are crucial for the progression of metabolic‐associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC) development. Recent research focused on the interplay between epigenetics and altered metabolic pathways in HCC from MASLD, suggesting that the reversibility of epigenetic changes offers ...
Chiara Aiello+7 more
wiley +1 more source
Higher levels of plasma phosphatidylcholine (17:0_18:1) raise the risk of developing Parkinson's disease. [PDF]
Su D+8 more
europepmc +1 more source
The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholine
Federica Gibellini, Terry K. Smith
semanticscholar +1 more source
Phosphatidylcholine–cholesterol acyltransferase in the ultracentrifugal residual protein fraction of rat plasma [PDF]
Michihiro Sugano
openalex +1 more source
Lipid metabolism and inflammation as key drivers in preterm birth: A comprehensive analysis
Abstract Objective To investigate the alterations in lipid metabolites and circulating inflammatory factors associated with preterm birth, elucidate their interactions, and uncover the underlying pathophysiologic mechanisms. By identifying potential predictive biomarkers and informing the development of effective therapeutic interventions, this ...
Shu Xiao, ChaoChao Wei
wiley +1 more source
Exploring the Causal Link Between Plasma Lipidome and Trigeminal Neuralgia Using Bidirectional Mendelian Randomization. [PDF]
Peng Y+6 more
europepmc +1 more source
Studies on Polydisperse Systems Using an Air-Driven Ultracentrifuge: Application to Phosphatidylcholine Vesicles [PDF]
R.G. Clarke, GR Eagle, Howlett Gj
openalex +1 more source
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu+8 more
wiley +1 more source